Importantly, our work shows that increased TGF-β bioactivity of basal serum from the severe OI patient can be modulated along the MSCs treatment, correlating with the beneficial effects exhibited by this patient (at clinical, molecular and cellular levels) after the cell therapy (Infante et al., 2021). Here, TGFB1 is linked to osteogenesis imperfecta.